GLP-1 Series: Week 2 Your Natural GLP-1 vs. GLP-1 Medications: What’s the Difference?

Last week, we talked about something many people don’t realize: GLP-1 is not something that was invented for weight-loss medication. Your body already makes it naturally.

GLP-1, or glucagon-like peptide-1, is a hormone released primarily from your intestines after you eat. It plays an important role in blood sugar regulation, digestion, appetite and fullness.

So what happens when someone takes a GLP-1 medication? Does the medication replace your natural GLP-1? Does your body stop making its own?

No. And this distinction is important.

Your Body Makes Its Own GLP-1

After you eat, specialized cells in your intestines release natural GLP-1.

Natural GLP-1 helps:

• Stimulate insulin secretion when blood glucose is elevated

• Reduce glucagon secretion

• Slow gastric emptying

• Communicate with the brain and digestive system to influence appetite and fullness

But natural GLP-1 has a very short life.

An enzyme called DPP-4 rapidly breaks it down, giving naturally produced active GLP-1 a half-life of only a few minutes.

Your body is designed to release it, use it and break it down quickly.

What Does a GLP-1 Medication Do?

This is where there is often confusion.

GLP-1 medications don’t simply make your naturally produced GLP-1 last longer.

And they don’t replace your body’s ability to make GLP-1.

Instead, medications such as semaglutide are GLP-1 receptor agonists. They are molecules designed to activate the same GLP-1 receptors that your natural hormone activates.

But there is a major difference.

These medications have been engineered to resist rapid breakdown and remain active much longer than naturally occurring GLP-1.

Natural active GLP-1 lasts minutes.

Some prescription GLP-1 receptor agonists have effects lasting for days, allowing certain formulations to be given once weekly.

Think of it this way:

Your body produces its own short-lived GLP-1 signal after eating.

The medication adds a separate, much longer-lasting signal to those receptors.

Your natural GLP-1 hasn’t suddenly been turned into a week-long hormone.

What About Mounjaro and Zepbound?

There’s another distinction worth understanding.

Tirzepatide, sold as Mounjaro and Zepbound, isn’t technically just a GLP-1 receptor agonist.

It activates receptors for two different incretin hormones: GLP-1 and GIP.

That’s why you’ll often hear tirzepatide described as a dual GIP/GLP-1 receptor agonist.

Why Does a Longer-Lasting Signal Matter?

Continued activation of these receptors can substantially affect appetite and digestion.

People may experience:

• Feeling full after eating smaller amounts

• Reduced hunger

• Reduced desire to eat

• Slower stomach emptying

• Improved blood glucose regulation

For some people, these effects can be dramatic.

But there’s an important misconception we need to address.

GLP-1 Medications Don’t Simply “Speed Up Your Metabolism”

These medications aren’t traditional fat-burning or metabolism-boosting drugs.

A major reason people lose weight is that they consume less food.

When hunger decreases and fullness increases, calorie intake can decrease substantially. Over time, that energy deficit can produce significant weight loss.

But eating dramatically less creates another important question:

What are you losing along with the body fat?

Weight loss isn’t automatically synonymous with improved body composition.

People losing significant amounts of weight can lose lean body mass as well as fat mass. That’s one reason adequate nutrition, protein and resistance exercise deserve attention during weight loss.

We’ll talk much more about that in Week 3.

What About Slowing the Stomach?

Delayed gastric emptying is another important part of this conversation.

GLP-1 receptor activation can slow the movement of food from the stomach into the small intestine, particularly early in treatment and depending on the medication and individual response.

This contributes to feelings of fullness, but gastrointestinal effects are also among the most common adverse effects of these medications.

These can include:

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Abdominal discomfort

There are also less common but potentially serious adverse effects and warnings associated with individual GLP-1 medications. Those risks deserve their own discussion rather than being minimized simply because these drugs can produce weight loss.

Medication Does Not Replace Nutrition and Exercise

Reducing appetite can make someone eat less.

But medication doesn’t automatically teach someone what to eat.

It doesn’t build muscle.

It doesn’t strengthen bones.

It doesn’t replace resistance training.

And it doesn’t automatically create sustainable nutrition habits.

Whether someone uses medication or chooses not to, the foundations of metabolic health remain important: adequate nutrition, sufficient protein and fiber, regular physical activity, resistance training, sleep and sustainable eating behaviors.

What Do We Know About Long-Term Safety?

GLP-1 receptor agonists aren’t brand-new medications. Some have been used in diabetes treatment for many years.

However, today’s widespread use of newer, higher-dose and dual-agonist medications for obesity means researchers continue to evaluate their safety in much larger populations and over longer periods.

These medications carry established warnings and precautions that vary by drug, including gastrointestinal adverse effects, gallbladder disease, pancreatitis and other potential complications. Some carry an FDA boxed warning concerning thyroid C-cell tumors based on animal studies; whether these drugs cause medullary thyroid carcinoma in humans has not been established.

There is a difference between saying “we haven’t identified a risk” and saying “a risk can never exist.”

Medicine evolves as longer-term data accumulate.

That is why continued research and surveillance matter.

The Bottom Line

Your body naturally makes GLP-1.

Taking a GLP-1 receptor agonist doesn’t simply make that natural hormone last longer, nor is there evidence that the medication routinely shuts off your body’s natural GLP-1 production.

Instead, the medication provides an additional molecule designed to activate GLP-1 receptors for substantially longer than your naturally occurring active GLP-1.

That prolonged signaling can reduce appetite, increase fullness, alter gastrointestinal function and improve blood glucose control.

There are potential benefits.

There are known side effects and risks.

And there are questions that continued long-term research will help answer.

Education isn’t about convincing someone to take a medication or convincing someone not to take it. It’s about understanding what the medication actually does so you can make an informed decision with your healthcare provider.

Coming in Week 3

You’re losing weight—but what are you actually losing?

We’ll look at fat loss versus lean mass loss, why muscle preservation matters, and why strength training and adequate nutrition become especially important during significant weight loss.

This article is for educational purposes and is not medical advice. Medication decisions should be discussed with a qualified healthcare professional.

Evidence sources: FDA prescribing information for semaglutide and tirzepatide, National Institutes of Health resources, American Diabetes Association scientific guidance, and peer-reviewed literature on GLP-1 physiology and receptor agonists.